These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

48 related items for PubMed ID: 21590009

  • 1. The effect of continuous infusion IL-1 alpha on carboplatin-induced thrombocytopenia and anti-tumor activity in RIF-1 tumor bearing mice.
    Yu W, Chang M, Vlock D, Furmanski P, Johnson C.
    Oncol Rep; 1997; 4(1):43-8. PubMed ID: 21590009
    [Abstract] [Full Text] [Related]

  • 2. Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model.
    Chang MJ, Yu WD, Reyno LM, Modzelewski RA, Egorin MJ, Erkmen K, Vlock DR, Furmanski P, Johnson CS.
    Cancer Res; 1994 Oct 15; 54(20):5380-6. PubMed ID: 7923169
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Platinum agents in the treatment of osteosarcoma: efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines.
    Robson H, Meyer S, Shalet SM, Anderson E, Roberts S, Eden OB.
    Med Pediatr Oncol; 2002 Dec 15; 39(6):573-80. PubMed ID: 12376980
    [Abstract] [Full Text] [Related]

  • 10. Diethyldithiocarbamate modulation of murine bone marrow toxicity induced by cis-diammine(cyclobutanedicarboxylato)platinum (II).
    Schmalbach TK, Borch RF.
    Cancer Res; 1989 Dec 01; 49(23):6629-33. PubMed ID: 2555048
    [Abstract] [Full Text] [Related]

  • 11. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
    Gemlo BT, Palladino MA, Jaffe HS, Espevik TP, Rayner AA.
    Cancer Res; 1988 Oct 15; 48(20):5864-7. PubMed ID: 3139285
    [Abstract] [Full Text] [Related]

  • 12. Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia.
    Gelin J, Moldawer LL, Lönnroth C, Sherry B, Chizzonite R, Lundholm K.
    Cancer Res; 1991 Jan 01; 51(1):415-21. PubMed ID: 1703040
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prediction of hematologic toxicity of carboplatin by creatinine clearance rate.
    Taguchi J, Saijo N, Miura K, Shinkai T, Eguchi K, Sasaki Y, Tamura T, Sakurai M, Minato K, Fujiwara Y.
    Jpn J Cancer Res; 1987 Sep 01; 78(9):977-82. PubMed ID: 3117753
    [Abstract] [Full Text] [Related]

  • 16. Synergistic antitumor activity of cisplatin and interleukin 1 in sensitive and resistant solid tumors.
    Braunschweiger PG, Basrur VS, Santos O, Markoe AM, Houdek PV, Schwade JG.
    Cancer Res; 1993 Mar 01; 53(5):1091-7. PubMed ID: 8439953
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.